Outcome of the Board Meeting dated 06th February 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Sandu Pharmaceuticals approved unaudited standalone financial results for Q3 FY26 (quarter ended Dec 31, 2025) and the nine-month period ended Dec 31, 2025. Revenue from operations for Q3 stood at Rs 1,876.09 lakhs, up modestly from Rs 1,837.20 lakhs in Q3 FY25 (~2% growth). Nine-month revenue was nearly flat at Rs 5,308.10 lakhs vs Rs 5,312.32 lakhs last year. Profit after tax for Q3 rose to Rs 67.51 lakhs from Rs 55.55 lakhs. Nine-month PAT jumped to Rs 172.27 lakhs from Rs 122.25 lakhs, a strong ~41% YoY growth, helped by lower material consumption costs. The auditor (M/s Dileep & Prithvi) issued a clean limited review report with no qualifications or emphasis of matter.
The standout positive is the ~41% jump in nine-month PAT despite flat revenue, indicating margin expansion and improved operational efficiency. For shareholders, this signals healthy bottom-line growth, though the lack of topline expansion is a mild concern. The clean auditor report with no qualifications removes any near-term red flags.